ReviewPediatric research2026
Safe use of human milk for preterms in the context of maternal polypharmacy: a framework to improve practices.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal pharmacotherapy during lactation is an ongoing research field, which relies on scientific evidence, pharmacological reasoning and extrapolation to support risk-to-benefit assessment. Typically, drugs are studied individually for potential effects on a nursing infant, with limited information on the preterm infant. Polypharmacy during lactation is still poorly studied, leaving healthcare professionals without any scientific guidance when consulting on human milk safety in this scenario. When focusing on a dyad of a postpartum mother on polypharmacy and a preterm infant, the benefits of mother's own milk (MOM) should be weighed against the unknown potential risks of polypharmacy during lactation. Within this setting of limited evidence, a framework to improve clinical and research practices is provided. Possible measures to minimize the risk of maternal (poly)pharmacy to the newborn include: multi-disciplinary prenatal counseling; preferring medications with low passage rate into human milk; relative rating of medications according to safety profile; and 'mixed feeding' (alternating between MOM and other types of feed, preferably donor human milk). These measures can be used to support shared informed decisions on the risk-to-benefit assessment. As the topic of polypharmacy during lactation is still poorly explored, a research agenda is suggested. IMPACT: Polypharmacy during lactation is poorly studied, and practical, evidence-based guidelines for healthcare professionals are lacking. Various methods can be employed to reduce exposure to medications through human milk, even more so when applied concomitantly: preference of medications with low passage into human milk, relative rating of medications according to known safety profile, or 'mixed feeding' where mother's own milk is alternated with other types of feed, preferably donor human milk. A framework to improve clinical and research practices on provision of human milk in the setting of maternal polypharmacy and prematurity as an added challenge is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.